Shore Capital Reiterates Hold Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by equities research analysts at Shore Capital in a report issued on Friday.
Other equities research analysts have also recently issued reports about the company. UBS AG set a GBX 5,150 ($66.86) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a report on Thursday, April 27th. HSBC Holdings plc reiterated a “reduce” rating and issued a GBX 4,200 ($54.52) price objective on shares of AstraZeneca plc in a report on Friday, May 5th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Berenberg Bank lifted their price objective on AstraZeneca plc from GBX 5,670 ($73.61) to GBX 5,850 ($75.94) and gave the stock a “buy” rating in a report on Wednesday, May 17th. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 5,500 ($71.40) price objective on shares of AstraZeneca plc in a report on Tuesday, May 23rd. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of GBX 4,932.67 ($64.04).
AstraZeneca plc (LON AZN) opened at 4447.00 on Friday. The company’s market capitalization is GBX 56.30 billion. The company’s 50-day moving average price is GBX 4,818.59 and its 200-day moving average price is GBX 4,863.31. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
In other news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.